A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

NCT04678648 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

134

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Malignant Solid Neoplasm
RAS Mutation
Lung Cancer
Colon Cancer
Glioblastoma
Pancreatic Cancer

Interventions

DRUG: RSC-1255 Dose Escalation
DRUG: RSC-1255 Dose Expansion

Sponsor

RasCal Therapeutics, Inc.